Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. The offering is expected… 

The global squalene industry generated $114.5 million in 2020, and is estimated to reach $241.6 million by 2030, witnessing a CAGR of 7.8% from 2021 to 2030. The squalene market is experiencing robust growth due to rising demand in cosmetics and pharmaceuticals for its moisturizing and anti-aging properties. Increased awareness of natural and sustainable ingredients is driving market expansion. Additionally, innovations in extraction techniques and applications are broadening its industry uses. Allied Market Research published a report, titled, „Squalene Market by Source (Animal, Vegetable, and Synthetic Biotechnology), End Use Industry (Cosmetics, Nutraceuticals, and Healthcare): Global Opportunity Analysis and Industry Forecast, 2021–2030.“ Squalene is a colorless, oily triterpene hydrocarbon that is found in many animals and plants, including sharks, olives, and sugarcane. Drivers, Restraints, and Opportunities:Rise of the cosmetics industry, surge in value and potential of dietary supplements, and usage of… 

The first real-world analysis of tinnitus patients treated with Lenire in the United States has been submitted to a journal for peer-review and is now available on an online pre-print server for health services, medRxiv.Real-world results are consistent with Lenire’s large-scale clinical trial results.91.5% of patients experienced clinically meaningful reduction in tinnitus after 12-weeks of treatment with Lenire.89.2% of patients indicated they benefited from treatment with Lenire.220 patient treatment results were analyzed for the review making the paper one of the largest real-world analyses of tinnitus patients ever conducted.